Literature DB >> 29771191

Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.

Jie Ping Schee1, Shanthi Viswanathan1.   

Abstract

We identified five female patients retrospectively with relapsing short-segment partial myelitis whose clinical and paraclinical features were suggestive of cord involvement of multiple sclerosis (MS)-type albeit not rigidly fulfilling the 2017 McDonald criteria. Notably, these patients had not developed any typical MS-like brain lesions despite repeated neuroimaging assessments over years. Comprehensive work-up for differential diagnoses of MS and other causes of transverse myelitis particularly neuromyelitis optica spectrum disorders had been consistently negative on longitudinal follow-up. Thus, we postulate a possible entity of pure spinal MS which may represent a novel forme fruste within the MS disease spectrum.

Entities:  

Keywords:  McDonald criteria; Multiple sclerosis; demyelination; disease-modifying therapies; pure spinal; short-segment partial myelitis

Mesh:

Substances:

Year:  2018        PMID: 29771191     DOI: 10.1177/1352458518775912

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  "A rose by any other name": does defining extreme phenotypes add to the management of multiple sclerosis?

Authors:  Evan A Jolliffe; Brian G Weinshenker
Journal:  Ann Transl Med       Date:  2018-10

2.  Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?

Authors:  Zélia Poullet; Julie Pique; Adil Maarouf; Clemence Boutiere; Audrey Rico; Sarah Demortiere; Pierre Durozard; Caroline Papeix; Elisabeth Maillart; Nicolas Collongues; Xavier Ayrignac; Helene Zephir; Romain Deschamps; Jonathan Ciron; Jean Pelletier; Romain Marignier; Bertrand Audoin
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-04-26

Review 3.  Advances in spinal cord imaging in multiple sclerosis.

Authors:  Marcello Moccia; Serena Ruggieri; Antonio Ianniello; Ahmed Toosy; Carlo Pozzilli; Olga Ciccarelli
Journal:  Ther Adv Neurol Disord       Date:  2019-04-22       Impact factor: 6.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.